Paxneury is used to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years when stimulant medicines are not appropriate or do not control their symptoms well enough. Paxneury is used as part of a comprehensive treatment programme that typically involves psychological, educational and other interventions. Paxneury contains the active substance guanfacine and is a ‘hybrid’ and a ‘generic’ medicine. This means that it is similar to a ‘reference medicine’ containing the same active substance, but there are certain differences between the two. The reference medicine for Paxneury is Intuniv. Paxneury is available in the same strengths as Intuniv (1, 2, 3 and 4 mg) as well as in the additional strengths 4,5 and 7 mg.
Therapeutic Indication
### Therapeutic indication Paxneury is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6‑17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Paxneury must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
Therapeutic Area (MeSH)
ATC Code
C02AC02
ATC Item
guanfacine
Pharmacotherapeutic Group
Antihypertensives
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| guanfacine hydrochloride | N/A | 胍法辛 |
EMA Name
Paxneury
Medicine Name
Paxneury
Aliases
N/ANo risk management plan link.
